A secondary analysis of the DOTS clinical trial found that higher dalbavancin exposure was correlated with improved clinical success rates at day 70 among patients with stabilized Staphylococcus aureus bacteremia. In a cohort of 97 patients who received dalbavancin, 77% achieved clinical success by day 70, with a notable increase in success rates for those with higher drug concentrations. The study highlights the potential importance of sustained dalbavancin levels, suggesting further research on personalized dosing strategies is warranted. Lead author Thomas P. Lodise emphasized the findings' hypothesis-generating nature.
